BioSpace News Archive

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced their ongoing collaboration with the International Foundation for Gastrointestinal Disorders (IFFGD) for Gastroparesis Awareness Month celebrated in August each year.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that management will participate in an upcoming investor conference.

A new phase II clinical trial validated the efficacy of Lunit’s AI biomarker, Lunit SCOPE IO, in predicting outcomes of immunotherapy in patients with nasopharyngeal carcinoma.

Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for auto-immune and rare diseases, today announced the appointment of Paul F. Truex to its Board of Directors, effective August 1, 2022 .

BioInvent International AB announces treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA).

Enteral feeding is the delivery of nutrients directly into the digestive tract through a feeding tube.

Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a synthetic model to potentially standardize the study of soluble amyloid beta oligomers (AβOs), toxic proteins that accumulate early in Alzheimer’s disease (AD).

7 Hills Pharma LLC was awarded a 3-year grant worth almost $3 million from the National Institute of Allergy and Infectious Diseases to progress its work with collaborator Dr. Nisha Garg from the University of Texas Medical Branch toward the creation of the first vaccine against Chagas disease.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.